Which daily symptoms during chemotherapy increase risk for ED visits or unplanned hospitalizations? In this paper led by recent MD Elizabeth Kairis, GI symptoms, shortness of breath, fatigue, & pain predicted risk of unplanned healthcare within the next 7 days: ascopubs.org/doi/10.1200/...

Can devices worn during chemotherapy capture prognostic information about physical function? We found that Fitbit metrics predicted overall survival, even after adjusting for clinician-rated performance status and patient-reported physical function: ascopubs.org/doi/10.1200/...

Pitt Med School student Svea Cheng is first author on this study with PaRC faculty member Carissa Low which asks "What is a good day for a patient with advanced cancer?" Learn the answer, now online in Supportive Care in Cancer #hpm #research :

Qualitative study led by extraordinary med student Svea Cheng explored the activities and experiences that characterize good days living with advanced cancer: link.springer.com/article/10.1...

Key findings from @carissalow.bsky.social's study were that Fitbit metrics like gait speed were related to patient-reported and performance-based physical functioning as well as fall risk even after adjusting for age and comorbidities. #hpm #hapc Link:

This paper, led by our amazing research coordinator Annie Bartel, describes initial efforts to visualize daily patient-reported symptom data alongside wearable sensor data collected from patients receiving chemotherapy. Patients who viewed their data most often were those new to chemotherapy.

New paper led by David Lazris (PGY-3) used daily diaries to explore activities associated with having a "good day" among patients living with Stage IV cancer. Day-to-day QoL fluctuated for each patient, and the specific activities correlated with good days varied from patient to patient

First paper from our NCI R37, led by med student (now Triple Board Resident) Sean McClaine, is out! We found that daily symptom & behavior monitoring using smartphones & wearable devices is feasible during chemotherapy BUT engagement varied based on demographic, clinical, & time-related factors